These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 19545900)

  • 1. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
    Arevalo JF; Sanchez JG; Fromow-Guerra J; Wu L; Berrocal MH; Farah ME; Cardillo J; Rodríguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):735-43. PubMed ID: 19189118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group.
    Arevalo JF; Garcia-Amaris RA; Roca JA; Sanchez JG; Wu L; Berrocal MH; Maia M;
    J Cataract Refract Surg; 2007 Dec; 33(12):2098-105. PubMed ID: 18053911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
    Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.
    Forte R; Cennamo GL; Finelli M; Farese E; D'Amico G; Nicoletti G; de Crecchio G; Cennamo G
    Eye (Lond); 2010 Aug; 24(8):1325-30. PubMed ID: 20300127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
    Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
    Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
    Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
    Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
    Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
    Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
    Takamura Y; Kubo E; Akagi Y
    Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.